Elucidation of Teicoplanin Interactions with Drug Targets Related to COVID-19

Faizul Azam

Department of Pharmaceutical Chemistry & Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia; faizulazam@gmail.com or f.azam@qu.edu.sa; Tel.: +966-50-2728652

Abstract: Teicoplanin is a glycopeptide antibiotic effective against several bacterial infections, has exhibited promising therapeutic efficiency against COVID-19 in vitro, and the rationale for its use in COVID-19 is yet to be recognized. Hence, in this study a number of molecular modeling techniques were employed to decrypt the mechanistic insight of teicoplanin interaction with several COVID-19 drug targets. Initially, molecular docking was employed to study the teicoplanin interaction with twenty-five SARS-CoV-2 structural and non-structural proteins which was followed by molecular mechanics/generalized Born surface area (MM/GBSA) computation for binding energy predictions of top ten models from each target. Amongst all macromolecular targets, the N-terminal domain of the nucleocapsid protein displayed the strongest affinity with teicoplanin showing binding energies of $-7.4$ and $-102.13$ kcal/mol, in docking and Prime MM/GBSA, respectively. Thermodynamic stability of the teicoplanin-nucleocapsid protein was further probed by molecular dynamics simulations of protein–ligand complex as well as unbounded protein in 100 ns trajectories. Post-simulation MM-GBSA computation of 50 frames extracted from simulated trajectories estimated an average binding energy of $-62.52 \pm 12.22$ kcal/mol. In addition, conformational state of protein in complex with docked teicoplanin displayed stable root-mean-square deviation/fluctuation. In conclusion, computational investigation of the potential targets of COVID-19 and their interaction mechanism with teicoplanin can guide the design of novel therapeutic armamentarium for the treatment of SARS-CoV-2 infection. However, additional studies are warranted to establish the clinical use or relapses, if any, of teicoplanin in the therapeutic management of COVID-19 patients.

Keywords: SARS-CoV-2; teicoplanin; docking; molecular dynamics; MM/GBSA

1. Introduction

The outbreak of COVID-19 pandemic in China, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) primarily spreads through close contact amongst people by sneezing, coughing, or by communicating verbally. The primary symptoms of the disease are fever, cough, fatigue, shortness of breath, and loss of smell. The complications of this disease include viral pneumonias, respiratory distress, and hypoxia [1]. The world is suffering due to lack of effective medicine. Therefore, there is an urgent need to figure out efficient medicine through drug discovery efforts [2,3].

Drug repurposing strategy is often used for recognizing novel usages of approved or investigational drugs because of several advantages such as lower risk of failure, reduced time for drug development, and lower investment needs [4]. Therefore, numerous antimalarials, antibacterials, antiparasitic agents, and antivirals are currently prevalent in pre-clinical as well as clinical investigations aimed at developing COVID-19 treatment by a drug repurposing approach [5]. In particular, a widely available FDA-approved antibiotic, teicoplanin (Figure 1), is among the molecule of interest as probable COVID-19 medicine. It belongs to the glycopeptide class of antibiotic having low toxicity profile in humans and hence routinely used in clinical practice for the treatment of bacterial infections. Interestingly, it has demonstrated antiviral efficacy against several kinds of viruses such as...
Ebola, MERS-CoV, and SARS-CoV [6]. Very recently, it has been reported that teicoplanin can thwart the cellular entry of SARS-CoV-2 at an impressive 1.66-µM concentration [7,8]. Furthermore, IC$_{50}$ value of 1.5 µM was recorded for inhibition of the SARS-CoV-2 main protease by teicoplanin [9].

Figure 1. Two-dimensional structural coordinate of teicoplanin (ACD/ChemSketch program version 2020.2.1, of Advanced Chemistry Development, Inc., Toronto, ON, Canada, was used for drawing the chemical structure).

Computer-aided drug design methods are extensively employed in drug design and discovery projects owing to several advantages such as rapid development process and reduced cost [10–12]. In particular, molecular docking coupled with molecular dynamics simulation studies are intended to decipher the mechanism of binding interactions at the molecular levels [13]. Rapid mechanistic insight is vital for understanding structure–activity relationship and leading to the optimization of the design and discovery of potential molecules [14–16]. In this study, several computational techniques such as molecular
docking, molecular mechanics/generalized Born surface area (MM-GBSA), and molecular dynamics simulation were exploited to inspect the binding interactions between teicoplanin and potential drug targets associated with SARS-CoV-2. The study is envisioned to assist in finding potential leads and accelerating drug development process for the treatment of novel coronavirus, COVID-19.

2. Experimental Section

The methodology adopted in this study has been outlined as flowchart in Figure 2.

Figure 2. An outline of the adopted methodology in this study. B3LYP: Becke’s three-parameter hybrid model, Lee–Yang–Parr correlation functional method; DFT: density functional theory; MM/GBSA: molecular mechanics/generalized Born surface area; ns: nano seconds; RMSD: root-mean-square deviation; RMSF: root-mean-square fluctuation.

2.1. Ligand Preparation

The molecular structure of teicoplanin was retrieved from PubChem database as two-dimensional coordinate in sdf format and converted to its three-dimensional conformation by means of Open Babel program [17]. Jaguar v10.9 of Schrodinger Suites 2020-3 was used for density functional theory (DFT)-based optimization by Becke’s three-parameter hybrid model, the Lee–Yang–Parr (B3LYP) method at the level of 6-31G [18,19]. The optimized structure of teicoplanin is presented in Figure 3. Prepare_ligand4.py module of MGL Tools 1.5.6 [20] was used for the preparation of ligand in pdbqt format after merging all non-polar hydrogens, defining rotatable bonds/torsion tree and adding Gasteiger charges.
Figure 3. Teicoplanin structure optimized by density functional theory (DFT) with Becke’s three-parameter hybrid model, the Lee–Yang–Parr (B3LYP) correlation functional method at 6-31G level (Jaguar v10.9 software of Schrodinger Suites 2020-3 was used). Color code: carbon—dark gray, hydrogen—light gray, nitrogen—blue, oxygen—red, and chlorine—green.

2.2. Protein Preparation

Twenty-five structural and non-structural protein targets related to SARS-CoV-2 were downloaded from the RCSB PDB repository as listed in Table 1. The macromolecular targets include main protease (M\textsuperscript{PrO}), papain-like protease (PL\textsuperscript{PrO}), RNA-dependent RNA polymerase (RdRp-RTP site), RdRp-RNA site, spike protein-receptor binding domain (RBD), spike trimer (open state), spike monomer (closed state), S2 protein in post-fusion state, N-protein (C-domain), N-protein (N-domain), Nsp3-AMP site, Nsp3-MES site, Nsp7, Nsp8, Nsp9, Nsp10, Nsp12, helicase (Nsp13-ADP site), helicase (Nsp13-NCB site), Nsp14 (N-terminal exoribonuclease; ExoN), Nsp14 (N7 methyltransferase; N7-MTase), Nsp15 (exoribonuclease), Nsp16 (GTA site), Nsp16 (MGP site), and Nsp16 (SAM site). All the protein structures were processed in Biovia Discovery Studio Visualizer 2020 [21] and PyMol 2.4.1 [22] for removing unwanted co-crystallized compounds including water molecules. MGLTools 1.5.6 [20] was utilized for generating input receptor files in pdbqt format.
Table 1. Docking-predicted binding energy ($\Delta G_{\text{Bind}}$) and grid parameters used for docking of teicoplanin with 25 potential COVID-19 drug targets.

| Target Number | Targets                | PDB ID | Grid Center for AutoDock Vina Program | Docking $\Delta G_{\text{Bind}}$ (kcal/mol) |
|---------------|------------------------|--------|---------------------------------------|---------------------------------------------|
| 1             | Main protease          | 6LU7   | −9.732 11.403 68.925                  | −5.4                                        |
| 2             | Papain-like protease   | 6WUU   | 22.225 68.703 4.704                   | −5.4                                        |
| 3             | RdRp (RTT site)        | 7BV2   | 91.776 91.560 104.863                 | −9.8                                        |
| 4             | RdRp (RNA site)        | 7BV2   | 71.227 92.269 112.852                 | −7.7                                        |
| 5             | Spike protein (RBD)    | 6MOJ   | −36.193 37.260 5.752                  | −6.1                                        |
| 6             | Spike monomer          | 6VXX   | 219.061 220.947 261.311               | −5.4                                        |
| 7             | Spike trimer           | 6VYB   | 251.872 195.411 243.040               | −6.9                                        |
| 8             | S2 protein (post fusion state) | 6LXT | −0.641 11.084 28.359                  | −5.3                                        |
| 9             | N-protein (C-domain)   | 6YUN   | −10.288 12.683 7.740                  | −5.6                                        |
| 10            | N-protein (N-domain)   | 6YI3   | 16.299 11.628 6.638                   | −7.4                                        |
| 11            | Nsp3 (AMP site)        | 6W6Y   | 9.124 8.677 16.220                   | −7.3                                        |
| 12            | Nsp3 (MES site)        | 6W6Y   | 23.830 9.255 54.812                   | −5.9                                        |
| 13            | Nsp7                   | 7BV2   | 104.782 80.343 127.861                | −4.4                                        |
| 14            | Nsp8                   | 7BV2   | 108.168 116.454 120.901               | −5.9                                        |
| 15            | Nsp9                   | 6WXD   | 53.119 10.095 22.482                  | −4.5                                        |
| 16            | Nsp10                  | 6WVN   | 64.644 15.650 9.322                   | −2.2                                        |
| 17            | Nsp12                  | 7BV2   | 97.382 97.966 93.920                  | −7.8                                        |
| 18            | Nsp13 (helicase ADP site) | 6YJT | 405.020 47.480 62.350                 | −6.5                                        |
| 19            | Nsp13 (helicase NCB site) | 6YJT | 423.816 33.797 56.132                 | −5.4                                        |
| 20            | Nsp14 (ExoN)           | 5CSS   | −39.712 −50.684 15.5994               | −7.1                                        |
| 21            | Nsp14 (N7mtase)        | 5CSS   | −10.273 −42.259 −7.644                | −3.0                                        |
| 22            | Nsp15 (Exoribonuclease) | 6WLH | 94.134 −19.803 −25.857                | −6.5                                        |
| 23            | Nsp16 (GTA site)       | 6WVN   | 84.158 24.757 37.836                  | −6.2                                        |
| 24            | Nsp16 (MGP site)       | 6WVN   | 100.029 38.995 18.481                 | −7.4                                        |
| 25            | Nsp16 (SAM site)       | 6WVN   | 84.156 15.450 26.991                  | −6.5                                        |

ADP site: adenosine diphosphate binding site; AMP: adenosine monophosphate; C-domain: carbon-terminal domain; ExoN: N-terminal exoribonuclease; GTA: P1-7-methylguanosine-P3-adenosine-5′,5′-triphosphate; MES: 2-(N-morpholino)-ethanesulfonic acid; MGP: 7-methyl-guanosine-5′-triphosphate; N-domain: nitrogen-terminal domain; N7mtase: N7 methyltransferase; NCB site: nucleic acids binding site; N-protein: nucleocapsid protein; Nsp: non-structural protein; PDB: protein data bank; RBD: receptor binding domain; RdRp: RNA-dependent RNA polymerase; RNA: ribonucleic acid; RTP: remdesivir; SAM: S-adenosylmethionine.

2.3. Molecular Docking Simulation

The grid box of $30 \times 30 \times 30$ size in x, y, and z directions with 1-Å spacing was constructed around the active site residues as demarcated by the bound co-crystallized ligands (see Table 1 for grid points used for each receptor). However, blind docking, covering the entire macromolecular target, was opted if binding site information was unavailable. AutoDock Vina 1.1.2 [23] was used for molecular docking employing default parameters for flexible ligand and rigid protein. Moreover, the exhaustiveness parameter was set to 12. Upon successful completion of docking simulation, ten best poses were individually analyzed for intermolecular interactions using PyMol 2.4.1 [22] and Biovia Discovery Studio Visualizer 2020 [16,21,24] and further subjected to MM/GBSA computations in the next step.

2.4. Prime MM-GBSA Calculations

MM-GBSA technique are frequently used to rationalize the findings of molecular docking and virtual screening. Prime MM-GBSA module of Schrödinger Suite 2020-3 [25–27] was used to compute binding energy and relevant parameters as presented in Table 2. The Prime MM-GBSA protocol amalgamates OPLS molecular mechanics energies, a VSGB solvation model for polar solvation ($G_{\text{SCB}}$), and a nonpolar solvation expression ($G_{\text{NP}}$) involving nonpolar solvent-accessible surface area (SASA) and van der Waals interactions [28].
The binding-free energy (\(\Delta G_{\text{bind}}\)) of docked teicoplanin in complex with respective proteins was calculated using the following equation [29]:

\[
\Delta G_{\text{bind}} = \Delta E_{\text{MM}} + \Delta G_{\text{solv}} + \Delta G_{S}
\]

where \(\Delta E_{\text{MM}}\) is the difference in energy between the complex structure and the sum of the energies of the protein with and without teicoplanin, \(\Delta G_{\text{solv}}\) is the difference in the GBSA solvation energy of the teicoplanin–protein complex and the sum of the solvation energies for the teicoplanin-bound and unbound protein, and \(\Delta G_{S}\) is the difference in the energy of surface area for the teicoplanin–protein complex and the sum of the surface area energies for the ligand and un-complexed protein.

### Table 2. Results of molecular mechanics/generalized Born surface area (MM/GBSA) computations for teicoplanin in complex with 25 potential COVID-19 targets.

| Target Number | Target | \(\Delta G_{\text{bind}}\) | \(\Delta G_{\text{Coul}}\) | \(\Delta G_{\text{HBond}}\) | \(\Delta G_{\text{Lipo}}\) | SolvGB | \(\Delta G_{\text{vdw}}\) | Lig SE |
|---------------|--------|----------------|----------------|----------------|----------------|--------|----------------|--------|
| 1 | Main protease | -97.55 | -19.11 | -0.68 | -59.81 | 44.25 | -68.46 | 3.87 |
| 2 | Papain-like protease | -78.75 | -39.06 | -3.33 | -58.73 | 54.34 | -42.74 | 39.85 |
| 3 | RdRp (RTP site) | 75.76 | -124.58 | -4.94 | -91.90 | 209.45 | -17.65 | 184.45 |
| 4 | RdRp (RNA site) | -86.33 | -68.97 | -6.24 | -13.97 | 78.93 | -83.45 | 10.54 |
| 5 | Spike protein (RBD) | -95.76 | -32.67 | -2.13 | -54.25 | 48.60 | -66.71 | 18.19 |
| 6 | Spike monomer | -68.38 | -61.51 | -4.39 | -13.35 | 55.98 | -50.51 | 12.74 |
| 7 | Spike trimer | -66.87 | -27.37 | -4.11 | -21.53 | 53.95 | -65.20 | 11.90 |
| 8 | S2 protein (post fusion state) | -36.93 | -23.22 | -2.74 | -14.11 | 55.19 | -61.27 | 24.45 |
| 9 | N-protein (C-domain) | -42.31 | -30.82 | -5.06 | -16.05 | 64.88 | -62.43 | 26.93 |
| 10 | N-protein (N-domain) | -102.13 | -40.95 | -6.98 | -24.95 | 61.07 | -78.69 | -0.90 |
| 11 | Nsp3 (AMP site) | -58.33 | -42.82 | -4.38 | -25.86 | 64.42 | -71.09 | 32.93 |
| 12 | Nsp3 (MES site) | -57.60 | -12.61 | -2.42 | -30.13 | 34.62 | -75.40 | 37.34 |
| 13 | Nsp7 | -66.61 | -54.39 | -4.15 | -19.17 | 55.49 | -60.78 | 8.43 |
| 14 | Nsp8 | -67.93 | -10.55 | -2.28 | -25.51 | 28.75 | -68.85 | 16.42 |
| 15 | Nsp9 | -66.83 | -43.87 | -3.59 | -19.55 | 46.75 | -57.02 | 10.15 |
| 16 | Nsp10 | -47.56 | -29.62 | -2.47 | -23.97 | 57.87 | -62.53 | 40.47 |
| 17 | Nsp12 | -87.84 | -96.33 | -8.48 | -19.26 | 135.75 | -108.20 | 8.52 |
| 18 | Nsp13 (helicase ADP site) | -41.57 | -63.94 | -7.00 | -19.36 | 88.70 | -53.79 | 16.23 |
| 19 | Nsp13 (helicase NCB site) | -53.99 | -42.21 | -4.05 | -26.40 | 87.73 | -78.57 | 7.39 |
| 20 | Nsp14 (ExoN) | -49.41 | -32.04 | -4.56 | -20.91 | 64.52 | -80.34 | 28.66 |
| 21 | Nsp14 (N7mtase) | -38.83 | -21.49 | -4.69 | -15.49 | 47.57 | -44.45 | 1.51 |
| 22 | Nsp15 (Exoribonuclease) | -64.40 | -48.67 | -6.39 | -23.20 | 47.29 | -55.77 | 43.43 |
| 23 | Nsp16 (GTA site) | -63.57 | -55.69 | -5.17 | -12.18 | 65.46 | -62.63 | 8.44 |
| 24 | Nsp16 (MGP site) | -58.94 | -31.42 | -3.89 | -22.67 | 59.61 | -79.15 | 30.67 |
| 25 | Nsp16 (SAM site) | -54.88 | -34.65 | -4.69 | -21.69 | 74.67 | -74.43 | 15.52 |

All the energy values are given in kcal/mol; \(\Delta G_{\text{bind}}\): binding-free energy; \(\Delta G_{\text{Coul}}\): Coulomb energy; \(\Delta G_{\text{HBond}}\): hydrogen-bonding correction; \(\Delta G_{\text{Lipo}}\): lipophilic energy; \(\Delta G_{\text{solv}}\): generalized Born electrostatic solvation energy; \(\Delta G_{\text{vdw}}\): Van der Waals energy; \(\Delta G_{\text{C}}\): AMPPPC energy; \(\Delta G_{\text{solv}}\): solvation energy; \(\Delta G_{S}\): surface energy; \(\Delta G_{\text{MM}}\): molecular mechanics energy; \(\Delta G_{\text{GBSA}}\): GBSA solvation energy.

#### 2.5. Molecular Dynamics Simulation

The best ranked conformation of teicoplanin in complex with N-protein–N-domain furnished by MM-GBSA experiments was further assessed for their thermodynamic behavior and stability by employing molecular dynamics (MD) simulation. Desmond 6.1 program integrated with Maestro (Schrodinger, Inc. LLC, New York, NY, USA) was used for MD simulation studies [30,31]. In addition, apo form of the N-protein–N-domain was also simulated in order to understand the conformational changes upon teicoplanin binding. The teicoplanin–protein complex was placed into an orthorhombic box of \(10 \times 10 \times 10\) Å size, filled with 7210 water molecules by means of simple point charge (SPC) model implemented in system setup protocol. An OPLS3 force field was applied for the MD computations [32]. The system was neutralized using 20 and 26 Na\(^+\) and Cl\(^-\) ions, respectively, with a salt concentration of 0.15 M that represents the physiological concentration of monovalent ions. An isothermal–isobaric (NPT) ensemble was utilized with temper-
ature and pressure attuned to 300 K and 1.01325 bar, respectively. A simulation time of 100 ns was adjusted, whereas trajectories were saved at every 100 ps. A cut-off radius of 9.0 Å was used for short-range van der Waals and Coulomb interactions. Nose–Hoover thermostat [33] and Martyna–Tobias–Klein [34] methods were employed for maintaining the system temperature and pressure, respectively. In order to integrate the equations of motion, an RESPA integrator was used with an inner time step of 2.0 fs for bonded as well as non-bonded interactions within the short-range cut-off [35]. The system was minimized and equilibrated with the default protocols of the Desmond. Simulation event analysis, simulation quality analysis, and simulation interaction diagram protocols of the Desmond package was exercised to analyze the trajectory files.

2.6. Post-Simulation MM-GBSA Analysis

Post-simulation MM-GBSA analysis was performed by using the thermal_MMGBSA.py script of the Prime/Desmond module of the Schrodinger suite 2020-3 [25,26]. From each MD trajectory, every tenth frame was extracted from the last 50 ns of simulated trajectory, averaging over 50 frames, for binding free energy calculations of teicoplanin in complex with N-protein–N-domain. The Prime MM-GBSA method uses the rule of additivity wherein total binding free energy (kcal/mol) represents a summation of individual energy modules like coulombic, covalent, hydrogen bond, van der Waals, self-contact, lipophilic, solvation, and π-π stackings of ligand and protein [36].

3. Results and Discussion

3.1. Validation of Docking Protocol

The co-crystallized ligand of main protease, N3, was redocked into the inhibitor binding cavity of the enzyme and docked conformation of the ligand was compared with that of the crystal structure in order to validate the docking protocol implemented in AutoDock Vina. The root-mean-square deviation (RMSD) was less than 2 Å between the docked and X-ray crystal structure conformations of N3, which authenticated the scoring functions implemented in the docking program (data not shown). According to the reported protocols, a successful docking computation should furnish the RMSD of ≤2.0 Å [10,14]. Therefore, AutoDock Vina used in this study was deemed reliable for studying teicoplanin interaction with potential SARS-CoV-2 targets.

3.2. Molecular Docking of Teicoplanin with Potential Targets of SARS-CoV-2

Molecular docking is a computational method of accelerating the early stages of drug discovery through unravelling the precise mechanism of intermolecular interactions of potential drug candidates by comparing their energetic compatibility and molecular shape with the target proteins [11,37]. With the aim of inspecting the interaction of teicoplanin with putative drug targets of SARS-CoV-2, docking studies was performed on the receptors/targets constituting both non-structural and structural proteins with prospective to be used in the drug discovery field [38,39]. Docking-predicted binding energies of teicoplanin with twenty-five COVID-19 drug targets are given in Table 1, whereas comprehensive intermolecular interactions have been listed in Table S1 in the Supplementary Information.

3.3. Prime MM-GBSA Calculations of Docked Complexes

Though several docking experiments are routinely employed to emphasize the binding mode and the affinity of a ligand relative to the protein, lack of accurate scoring function is one of the drawbacks of these algorithms. Therefore, MM-GBSA computations are routinely employed as a post-docking analysis in order to avoid false negatives as well as false positives [40,41]. The top ten conformations of protein-teicoplanin-docked complexes of each target were subjected to molecular mechanics/generalized Born surface area (MM-GBSA) computation for estimation of more accurate free binding energies. Table 2 enlists the MM-GBSA computed energies of best conformation of teicoplanin in complex with each target. Several other energy components such as Coulomb energy, hydrogen-bonding...
correction, lipophilic energy, generalized Born electrostatic solvation energy, Van der Waals energy, and ligand strain energy were also computed. Moreover, an elaborated MM-GBSA calculation of all poses has been listed in Table S2 in the Supplementary Information.

As presented in Figure 4, nucleocapsid protein N-terminal domain ranked top among all studied targets exhibiting \( \Delta G_{\text{bind}} = -102.13 \text{ kcal/mol} \) followed by main protease and spike protein-RBD with binding energies of \(-97.55\) and \(-95.76\) kcal/mol, respectively. However, MM-GBSA binding energy of teicoplanin-main protease complex obtained from AutoDock 4.2 has been recently reported as \(-68\) kcal/mol. Interestingly, RdRp-RTP site was rendered as least promising for teicoplanin in this study, demonstrating 75.8 kcal/mol binding energy. The most promising target also hosted ample non-bond interactions with teicoplanin within the active site of N-domain of the N-protein. Moreover, appreciable intermolecular forces were established with all other targets. It is evident that the N-domain of the N-protein hosts nucleic acid substrates during processing of the viral genome into a ribonucleoprotein unit. Therefore, targeting this protein by teicoplanin can interrupt crucial steps of the SARS-CoV-2 life cycle such as transcription and translation processes [42]. Several proteins such as Nsp12, RdRp-RNA site, and papain-like protease were ranked as moderately favorable targets, whereas variable affinity was noted against the rest of the targets. The chemical structure of teicoplanin represents a unique blend of polar groups in the form of several amino acid fragments, carbohydrate cores such as N-acetylglucosamine, β-D-glucosamine and mannose, and non-polar fragments such as fatty acyl side-chain and numerous aromatic rings. These moieties enabled teicoplanin to interact with diverse drug targets of COVID-19 which warrants further experimental validation and may be useful in drug design based on teicoplanin template. Intermolecular interactions observed after MM-GBSA computation of all studied targets are presented in Figures S1–S4 and Table S1 in the Supplementary Information.

![Figure 4](image_url)

**Figure 4.** Bar plot showing comparative affinity of teicoplanin against drug targets associated with COVID-19 (please refer to Table 2 for target names against respective numbers). The analysis is based on molecular mechanics–generalized Born surface area (MM-GBSA) computed binding energy (\( \Delta G_{\text{bind}} \)) in kcal/mol.
3.4. Molecular Dynamics Simulation Studies

Dynamic and thermodynamics parameters of living systems under specific conditions of physiological environments can be estimated by the application of molecular dynamics (MD) simulation, a widely employed computer-aided drug design technique [11,13,14,43]. Therefore, the best docked pose of teicoplanin in complex with SARS-CoV-2 nucleocapsid protein N-terminal domain was subjected to MD simulation study in order to investigate the stability of the ligand–protein complex as well as main intermolecular interactions during the simulated trajectory. MM-GBSA-optimized pose bearing minimum binding energy was selected for MD simulation study. Desmond software was employed for the MD simulation of 100 ns in explicit solvent system. The resulting trajectories of the simulated complex was inspected for different standard simulation parameters such as backbone RMSDs for alpha-carbons, side chains, and heavy atoms. In addition, the root-mean-square fluctuations (RMSFs) of individual amino acid residue and intermolecular interactions involved were also evaluated. Figure 5A shows the RMSD of Cα atoms of apo protein whereas the complex of teicoplanin bound to N-protein–N-domain is presented as Figure 5B. The analysis of RMSD of teicoplanin-bound protein indicates that the simulated system fluctuated initially during 0–22 ns but acquired stability during rest of the simulated time. However, fluctuations can be clearly seen in the RMSD plot of the apo protein alone (Figure 5A). Therefore, it seems logical to infer that upon teicoplanin binding, the protein maintains its conformational stability when simulated for 100 ns period. The conformational changes observed during simulated path has been visualized by the snapshots taken at the intervals of every 20 ns and presented in Figure 6.

The MM-GBSA method exploits molecular mechanics, the generalized Born solvation models and a solvent accessibility approach to estimate the free energies of binding based on snapshots obtained from MD simulations [40,44]. MM-GBSA computation was performed for the last 50 snapshots of 100 ns simulation, which estimated an average binding energy of $-62.52 \pm 12.22$ kcal/mol.

The local conformational alterations along SARS-CoV-2 nucleocapsid protein N-domain were investigated by analyzing the RMSF during simulation time. Terminal residues fluctuated most in both bound and unbound states. Maximum fluctuation was noted with Gly1 as 13.29 Å which was declined upon teicoplanin binding at 7.00 Å (Figure 7). Key residues involved in hydrogen bonding showed fluctuations at 3.74, 2.97, 1.76, 1.54, 4.12, 0.96, and 2.68 Å by Asn7, Asn8, Thr9, Ser11, Arg55, Tyr69, and Pro111, respectively.

Simulation interactions diagrams presented in Figures 8 and 9 during entire simulation time signifies a comprehensive intermolecular interaction profile of teicoplanin with nucleocapsid protein N-domain. The modus of interaction pattern of teicoplanin illustrates that only fewer docking-predicted main contacts were retained upon MD simulation time of 100 ns. Figure 8 presents intermolecular interactions observed in first and last frames of the teicoplanin bound to nucleocapsid protein N-domain. Residues participating in both hydrogen bonding and water bridges include Asn7, Asn8, Thr9, Ser11, Thr51, Arg53, Arg55, Tyr71, Pro111, and Asn114. In addition, Thr51, Arg53, Arg55, and Arg67 also contributed in ionic bond interaction. However, amino acid residues Ala10, Ala50, Tyr69, and Ala112 were noted to be important for hydrophobic interaction.
performed for the last 50 snapshots of 100 ns simulation, which estimated an average binding energy of $-62.52 \pm 12.22$ kcal/mol.

Figure 5. The root-mean-square deviations (RMSD) of C$_\alpha$ atoms of N-protein–N-domain in unbound state (A) and teicoplanin-bound state (B) during 100 ns molecular dynamics simulation.

Figure 5. The root-mean-square deviations (RMSD) of C$_\alpha$ atoms of N-protein–N-domain in unbound state (A) and teicoplanin-bound state (B) during 100 ns molecular dynamics simulation.
Figure 6. Molecular dynamics (MD) simulation snapshots of teicoplanin (shown as ball and stick style in green color) in complex with nucleocapsid protein N-domain (depicted as solid ribbon) showing conformational stability (Initial: (A); after 20 ns: (B); 40 ns: (C); 60 ns: (D); 80 ns: (E); and 100 ns: (F)).
The local conformational alterations along SARS-CoV-2 nucleocapsid protein N-domain were investigated by analyzing the RMSF during simulation time. Terminal residues fluctuated most in both bound and unbound states. Maximum fluctuation was noted with Gly1 as 1.32 Å which was declined upon teicoplanin binding at 7.00 Å (Figure 7).

Key residues involved in hydrogen bonding showed fluctuations at 3.74, 2.97, 1.76, 1.54, 4.12, 0.96, and 2.68 Å by Asn7, Asn8, Thr9, Ser11, Arg55, Tyr69, and Pro111, respectively.

Figure 7. Root-mean-square fluctuations (RMSF) of SARS-CoV-2 nucleocapsid protein N-domain during 100 ns molecular dynamics simulation in apo form (A) and teicoplanin bound form (B).

Figure 7. Root-mean-square fluctuations (RMSF) of SARS-CoV-2 nucleocapsid protein N-domain during 100 ns molecular dynamics simulation in apo form (A) and teicoplanin bound form (B).
Figure 8. Non-bond interactions observed in first (A,B) and last (C,D) frames extracted from 100 ns molecular dynamics simulation of teicoplanin bound nucleocapsid protein N-domain of SARS-CoV-2. Ala: alanine; Arg: arginine; Asn: asparagine; Leu: leucine; Met: methionine; Pro: proline; Ser: serine; Thr: threonine; Tyr: tyrosine. The number of corresponding amino acid residue is in accordance with the crystallographic information obtained from the protein data bank.

Figure 9. Protein interactions with teicoplanin, monitored throughout the simulation trajectory. These interactions are clustered by type and summarized in bar diagram including hydrogen bonds (H-bonds), hydrophobic, ionic, and water bridges. Ala: alanine; Arg: arginine; Asn: asparagine; Asp: aspartic acid; Cys: cysteine; Gln: glutamine; Glu: glutamic acid; Gly: glycine; His: histidine; Leu: leucine; Met: methionine; Phe: phenylalanine; Pro: proline; Ser: serine; Thr: threonine; Tyr: tyrosine; Val: valine. The number of corresponding amino acid residue is according to the crystallographic information obtained from the protein data bank.
4. Conclusions

By using computer-aided drug design techniques, the current study explained the intermolecular interaction of the antibacterial drug, teicoplanin, with potential drug targets of SARS-CoV-2. Molecular docking studies employing AutoDock Vina highlighted the importance of hydrophilic and hydrophobic interactions in supporting the teicoplanin molecule inside the nucleocapsid protein N-domain binding cavity. MM-GBSA analysis and molecular dynamics simulation results not only reinforce the credibility of the docking results, but also authenticate the stability of the simulated system. This study is expected to assist lead optimization and design of COVID-19 drugs based on molecular skeleton of teicoplanin. However, the requirement of additional experimental and clinical validation is an obvious limitation of this study. Nevertheless, findings of this study justify further exploration of teicoplanin repurposing.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/antibiotics10070856/s1, Figure S1: MM/GBSA optimized complexes of teicoplanin (displayed as stick) showing non-bond interactions with main protease (A), papain-like protease (B), RdRp-RTP site (C), RdRp-RNA site (D), spike protein-RBD (E), and spike monomer (F). Broken green lines enumerate hydrogen bonds whereas purple lines justify hydrophobic interactions; Figure S2: Non-bond interactions of teicoplanin (portrayed as stick style) with spike trimmer (A), S2 protein-post fusion state (B), N-protein–C-domain (C), Nsp3-AMP site (D), Nsp3-MES site (E), and Nsp7 (F) in MM/GBSA optimized complexes. Hydrogen bonds are shown by broken green lines and purple lines enumerate hydrophobic interactions; Figure S3. Intermolecular interactions of teicoplanin (shown in stick style) with Nsp8 (A), Nsp9 (B), Nsp10 (C), Nsp12 (D), Nsp13 helicase-ADF site (E), and Nsp13 helicase-NCB site (F) after MM/GBSA computations. Hydrogen bonds are represented by broken green lines and purple lines specify non-polar interactions; Figure S4. Intermolecular complexes of teicoplanin (shown as sticks) with Nsp14 N-exoribonuclease (A), Nsp14 N7-methyl transferase (B), Nsp15 exoribonuclease (C), Nsp16-GTA site (D), Nsp16-MGP site (E), and Nsp16-SAM site (F) resulted after MM-GBSA analysis showing hydrogen bonds (broken green lines) and non-polar contacts (purple lines); Table S1: Intermolecular interactions observed in MM/GBSA optimized complexes of teicoplanin and 25 potential COVID-19 targets (AutoDock Vina 1.1.2 was used for molecular docking); Table S2. Computation of MM/GBSA energies of top ten docked poses of teicoplanin in complex with 25 potential COVID-19 targets.

**Funding:** The author gratefully acknowledges the Deanship of Scientific Research, Qassim University, Saudi Arabia for funding the publication of this research.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Acknowledgments:** The author gratefully acknowledges the Deanship of Scientific Research, Qassim University, Saudi Arabia for funding the publication of this research. The author further extends sincere thanks to Schrodinger India for providing the access to Schrodinger Suite 2020-3. Prajwal Nandeekar and Sudharshan Pandiyan are kindly acknowledged for their help and support.

**Conflicts of Interest:** The author declares no conflict of interest.

**References**

1. Barkoff, C.M.; Mousa, S.A. Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System. *Biomedicines* 2021, 9, 11. [CrossRef]
2. Raoult, D.; Hsueh, P.-R.; Stefani, S.; Rolain, J.-M. COVID-19 Therapeutic and Prevention. *Int. J. Antimicrob. Agents* 2020, 55, 105937. [CrossRef]
3. Clinical Management of COVID-19. Available online: https://www.who.int/publications/i/item/clinical-management-of-covid-19 (accessed on 31 December 2020).
4. Pushpakom, S.; Iorio, F.; Eyers, P.A.; Escott, K.J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; et al. Drug repurposing: Progress, challenges and recommendations. *Nat. Rev. Drug Discov.* 2019, 18, 41–58. [CrossRef] [PubMed]
5. Harrison, C. Coronavirus puts drug repurposing on the fast track. *Nat. Biotechnol.* 2020, 38, 379–381. [CrossRef]
6. Zhou, N.; Pan, T.; Zhang, J.; Li, Q.; Zhang, X.; Bai, C.; Huang, F.; Peng, T.; Zhang, J.; Liu, C.; et al. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). *J. Biol. Chem.* **2016**, *291*, 9218–9232. [CrossRef]

7. Baron, S.A.; Devaux, C.; Colson, P.; Raoult, D.; Rolain, J.-M. Teicoplanin: An alternative drug for the treatment of COVID-19? *Int. J. Antimicrob. Agents* **2020**, *55*, 109944. [CrossRef]

8. Zhang, J.; Ma, X.; Yu, F.; Liu, J.; Zou, F.; Fan, T.; Zhang, H. Teicoplanin potently blocks the cell entry of 2019-nCoV. *bioRxiv* **2020**. [CrossRef]

9. Tripathi, P.K.; Upadhyay, S.; Singh, M.; Raghavendhara, S.; Bhardwaj, M.; Sharma, P.; Patel, A.K. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2. *Int. J. Biol. Macromol.* **2020**, *164*, 2622–2631. [CrossRef]

10. Hussain, M.S.; Azam, F.; Ahamed, K.F.H.N.; Ravichandiran, V.; Alkskas, I. Anti-endotoxin effects of terpenoids fraction from Hygrophiura auriculata in lipopolysaccharide-induced septic shock in rats. *Pharm. Biol.* **2016**, *54*. [CrossRef] [PubMed]

11. Azam, F.; Alabdullah, N.H.; Ehmedat, H.M.; Abulifa, A.R.; Taban, I.; Upadhyayula, S. NSAIDs as potential treatment option for preventing amyloid β toxicity in Alzheimer’s disease: An investigation by docking, molecular dynamics, and DFT studies. *J. Biomol. Struct. Dyn.* **2018**, *36*, 2099–2117. [CrossRef]

12. Azam, F.; Taban, I.M.; Eid, E.E.M.; Iqbal, M.; Alam, O.; Khan, S.; Mahmood, D.; Anwar, M.J.; Khalilullah, H.; Khan, M.U. An in-silico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin α. *J. Biomol. Struct. Dyn.* **2020**, 1–14. [CrossRef]

13. Sandomenico, A.; Di Rienzo, L.; Calvanese, L.; Iaccarino, E.; D’Auria, G.; Falciigno, L.; Chambery, A.; Russo, R.; Franzoso, G.; Tornatore, L.; et al. Insights into the Interaction Mechanism of DTP3 with MKK7 by Using STD-NMR and Computational Approaches. *Biomédicas* **2021**, *9*, 20. [CrossRef]

14. Azam, F.; Abodabos, H.S.; Taban, I.M.; Rieda, A.R.; Mahmood, D.; Anwar, M.J.; Khan, S.; Sizochenko, N.; Poli, G.; Tuccinardi, T.; et al. Rutin as promising drug for the treatment of Parkinson’s disease: An assessment of MAO-B inhibitory potential by docking, molecular dynamics and DFT studies. *Mol. Simul.* **2019**, *45*. [CrossRef]

15. Shushni, M.A.M.; Azam, F.; Lindequist, U. Oxasetin from Lophiostoma sp. of the Baltic Sea: Identification, in silico binding mode prediction and antibacterial evaluation against fish pathogenic bacteria. *Nat. Prod. Commun.* **2013**, *8*, 1223–1226. [CrossRef] [PubMed]

16. Azam, F.; Vijaya Vara Prasad, M.; Thangavel, N.; Kumar Shrivastava, A.; Mohan, G. Structure-Based Design, Synthesis and Molecular Modeling Studies of Thiazolyl Urea Derivatives as Novel Anti-Parkinsonian Agents. *Med. Chem. (Los Angeles)* **2012**, *8*, 1057–1068.

17. O’Boyle, N.M.; Banck, M.; James, C.A.; Morley, C.; Vandermeersch, T.; Hutchison, G.R. Open Babel: An open chemical toolbox. *J. Cheminf.* **2011**, *3*, 33. [CrossRef] [PubMed]

18. Bochevarov, A.D.; Harder, E.; Hughes, T.F.; Greenwood, J.R.; Braden, D.A.; Philipp, D.M.; Rinaldo, D.; Halls, D.M.; Zou, F.; et al. Insights into the Interaction Mechanism of DTP3 with MKK7 by Using STD-NMR and Computational Approaches. *Biomédicas* **2021**, *9*, 20. [CrossRef]

19. Schrödinger Release 2020-3: Jaguar; Schrödinger, LLC: New York, NY, USA, 2020.

20. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective flexibility. *J. Comput. Chem.* **2009**, *30*, 2785–2791. [CrossRef] [PubMed]

21. BIOVIA, Dassault Systèmes, Discovery Studio Visualizer, Version 20.1.0.19295; Dassault Systèmes: San Diego, CA, USA, 2020.

22. The PyMOL Molecular Graphics System, Version 2.0; Schrödinger, LLC: New York, NY, USA, 2020.

23. Trotta, O.; Olson, A.J. AutoDock Vina: Improving the speed of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **2010**, *31*, 455–461. [CrossRef] [PubMed]

24. Fahmy, N.M.; Al-Sayed, E.; Moghannem, S.; Azam, F.; El-Shazly, M.; Singab, A.N. Breaking Down the Barriers to a Natural Antiviral Agent: Antiviral Activity and Molecular Docking of Erythrina speciosa Extract, Fractions, and the Major Compound. *Chem. Biol. Interact.* **2020**, *17*. [CrossRef]

25. Jacobson, M.P.; Pincus, D.L.; Rapp, C.S.; Day, T.J.F.; Honig, B.; Shaw, D.E.; Friesner, R.A. A hierarchical approach to all-atom protein loop prediction. *Proteins* **2004**, *55*, 351–367. [CrossRef]

26. Jacobson, M.P.; Friesner, R.A.; Xiang, Z.; Honig, B. On the Role of the Crystal Environment in Determining Protein Side-chain Conformations. *J. Mol. Biol.* **2002**, *320*, 597–608. [CrossRef]

27. Schrödinger Release 2020-3; Schrödinger, LLC: New York, NY, USA, 2020; pp. 19–27.

28. Vijayakumar, B.; Parasuraman, S.; Ravendran, R.; Velmurugan, D. Identification of natural inhibitors against angiotensin I converting enzyme for cardiac safety using induced fit docking and MM-GBSA studies. *Pharmacog. Mag.* **2014**, *10*, 5639.

29. Lyne, P.D.; Lamb, M.L.; Saeh, J.C. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. *J. Med. Chem.* **2006**, *49*, 4805–4808. [CrossRef]

30. Schrödinger Release 2020-3: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2020. *Maestro-Desmond Interoperability Tools; Schrödinger*: New York, NY, USA, 2020.
32. Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J.Y.; Wang, L.; Lupyan, D.; Dahlgren, M.K.; Knight, J.L. OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. *J. Chem. Theory Comput.* 2016, 12, 281–296. [CrossRef]

33. Hoover, W.G. Canonical dynamics: Method for simulations in the canonical ensemble. *Phys. Rev. A* 1985, 31, 1695–1697. [CrossRef] [PubMed]

34. Martyna, G.J.; Tobias, D.J.; Klein, M.L. Constant pressure molecular dynamics algorithms. *J. Chem. Phys.* 1994, 101, 4177–4189. [CrossRef]

35. Humphreys, D.D.; Friesner, R.A.; Berne, B.J. A multiple-time-step molecular dynamics algorithm for macromolecules. *J. Phys. Chem.* 1994, 98, 6885–6892. [CrossRef]

36. Dill, K.A. Additivity Principles in Biochemistry. *J. Biol. Chem.* 1997, 272, 701–704. [CrossRef] [PubMed]

37. Azam, F.; Amer, A.M.; Rabulifa, A.; Elzwawi, M.M. Ginger components as new leads for the design and development of novel multi-targeted anti-Alzheimer’s drugs: A computational investigation. *Drug Des. Dev. Ther.* 2014, 8, 2045–2059. [CrossRef]

38. Gordon, D.E.; Jang, G.M.; Bouhaddou, M.; Xu, J.; Obernier, K.; White, K.M.; O’Meara, M.J.; Rezelj, V.V.; Guo, J.Z.; Swaney, D.L.; et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* 2020, 583, 459–468. [CrossRef]

39. Kong, R.; Yang, G.; Xue, R.; Liu, M.; Wang, F.; Hu, J.; Guo, X.; Chang, S. COVID-19 Docking Server: A meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19. *Bioinformatics* 2020. [CrossRef] [PubMed]

40. Genheden, S.; Ryde, U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. *Expert Opin. Drug Discov.* 2015, 10, 449–461. [CrossRef] [PubMed]

41. Sgobba, M.; Caporuscio, F.; Anighoro, A.; Portioli, C.; Rastelli, G. Application of a post-docking procedure based on MM-PBSA and MM-GBSA on single and multiple protein conformations. *Eur. J. Med. Chem.* 2012, 58, 431–440. [CrossRef]

42. Dinesh, D.C.; Chalupska, D.; Silhan, J.; Koutna, E.; Nencka, R.; Veverka, V.; Boura, E. Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein. *PLoS Pathog.* 2020, 16, 1–16. [CrossRef]

43. Hospital, A.; Goñi, J.R.; Orozco, M.; Gelpi, J.L. Molecular dynamics simulations: Advances and applications. *Adv. Appl. Bioinform. Chem.* 2015, 8, 37–47. [PubMed]

44. Kollman, P.A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; et al. Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. *Acc. Chem. Res.* 2000, 33, 889–897. [CrossRef] [PubMed]